Inclusion Criteria

          1. Age ≥ 18 years at the time of screening

          2. World Health Organization/Eastern Cooperative Oncology Group (ECOG) performance status
             of 0 or 1 at enrollment

          3. Life expectancy ≥ 12 weeks

          4. Histologically or cytologically-confirmed advanced solid tumors

          5. Subjects who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy or any
             concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy
             for cancer treatment may be eligible to enter the study following a washout period as
             applicable

          6. Females of childbearing potential who are sexually active with a nonsterilized male
             partner must use at least one highly effective method of contraception

          7. Nonsterilized males who are sexually active with a female partner of childbearing
             potential must use a male condom with spermicide where locally available from Day 1
             and for 90 days after the final dose of investigational product. Males receiving
             pemetrexed or carboplatin must use contraception during study treatment and up to 6
             months thereafter.

          8. Subjects must have at least one measurable lesion

          9. Adequate organ and marrow function

         10. Written informed consent and any locally required authorization

         11. Subjects must provide tumor material as applicable

        Exclusion Criteria

          1. Involvement in the planning and/or conduct of the study (applies to both MedImmune
             staff and/or staff at the study site)

          2. Concurrent enrollment in another clinical study, unless it is an observational
             clinical study or the follow-up period of an interventional study

          3. For subjects who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4:

               1. Subjects must not have received anti-PD-1, anti-PD-L1, anti-CTLA-4 or any other
                  immunotherapy or immune-oncology (IO) agent within 21 days of commencing
                  treatment with investigational product.

               2. Subject must not have experienced a toxicity that led to permanent
                  discontinuation of prior immunotherapy.

               3. All AEs while receiving prior immunotherapy must have completely resolved or
                  resolved to Grade 1 prior to screening for this study.

          4. Current or prior use of immunosuppressive medication within 14 days before the first
             dose of investigational product is excluded.

          5. Receipt of live attenuated vaccine within 30 days prior to the first dose of
             investigational product.

          6. Active or prior documented autoimmune or inflammatory disorders

          7. History of active primary immunodeficiency:

          8. History of organ transplant

          9. Known allergy or reaction to any component of the planned study treatment.

         10. Untreated CNS metastatic disease, leptomeningeal disease, or cord compression

         11. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to
             NCI CTCAE v4.03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion
             criteria

         12. Major surgical procedure (as defined by the investigator) within 28 days prior to the
             first dose of Investigational Product or still recovering from prior surgery

         13. Female subjects who are pregnant or breastfeeding, as well as male or female subjects
             of reproductive potential who are not willing to employ one highly effective method of
             birth control

         14. Uncontrolled intercurrent illness, that would limit compliance with study requirement,
             substantially increase risk of incurring AEs or compromise the ability of the subject
             to give written informed consent.

         15. Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the investigational product or interpretation of the subject's safety or
             study results

         16. Judgment by the investigator that the subject is unsuitable to participate in the
             study and the subject is unlikely to comply with study procedures, restrictions, and
             requirements.